Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Essler

Showing results (101-110 of 208) with videos related to

Pageof 21
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|November 23, 2006
IL-22-mediated tumor growth reduction correlates with inhibition of ERK1/2 and AKT phosphorylation and induction of cell cycle arrest in the G2-M phaseGeorg F Weber, Florian C Gaertner, Wolfgang Erl, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 24, 2016
<sup>68</sup>Ga-PSMA-11 PET as a Gatekeeper for the Treatment of Metastatic Prostate Cancer with <sup>223</sup>Ra: Proof of ConceptHojjat Ahmadzadehfar, Kambiz Azgomi, Stefan Hauser, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 27, 2018
Outcome and safety of rechallenge [<sup>177</sup>Lu]Lu-PSMA-617 in patients with metastatic prostate cancerAnna Yordanova, Paula Linden, Stefan Hauser, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 4, 2007
Postacquisition detection of tumor motion in the lung and upper abdomen using list-mode PET data: a feasibility studyRalph A Bundschuh, Axel Martínez-Moeller, Markus Essler, et al.
Oncotarget|May 2, 2019
Diagnosis of peri-prosthetic loosening of total hip and knee arthroplasty using <sup>18</sup>F-Fluoride PET/CTSebastian Koob, Florian C Gaertner, Tom Rainer Jansen, et al.
International Journal of Molecular Sciences|August 12, 2023
Cytokine-Induced Killer Cells in Combination with Heat Shock Protein 90 Inhibitors Functioning via the Fas/FasL Axis Provides Rationale for a Potential Clinical Benefit in Burkitt's lymphomaFangfang Ge, Yulu Wang, Amit Sharma, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 23, 2018
<sup>68</sup>Ga-PSMA-PET/CT imaging of localized primary prostate cancer patients for intensity modulated radiation therapy treatment planning with integrated boostLena Thomas, Steffi Kantz, Arthur Hung, et al.
Nuklearmedizin. Nuclear Medicine|April 29, 2020
[177Lu]Lu-DOTA-zoledronate therapy - first application in a patient with primary osseous metastatic bronchial carcinomaBarbara Kreppel, Florian Christoph Gaertner, Hojjat Ahmadzadehfar, et al.
Annals of Nuclear Medicine|March 17, 2019
Preliminary results of biodistribution and dosimetric analysis of [<sup>68</sup>Ga]Ga-DOTA<sup>ZOL</sup>: a new zoledronate-based bisphosphonate for PET/CT diagnosis of bone diseasesAmbreen Khawar, Elisabeth Eppard, Frank Roesch, et al.
Frontiers in Nuclear Medicine|October 2, 2024
Multicentric <sup>68</sup>Ga-PSMA PET radiomics for treatment response assessment of <sup>177</sup>Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancerRobin Gutsche, Gizem Gülmüs, Felix M Mottaghy, et al.
Pageof 21

Showing results (101-110 of 208) with videos related to

Sort By:
Pageof 21
Journal of Immunology (Baltimore, Md. : 1950)|November 23, 2006
IL-22-mediated tumor growth reduction correlates with inhibition of ERK1/2 and AKT phosphorylation and induction of cell cycle arrest in the G2-M phaseGeorg F Weber, Florian C Gaertner, Wolfgang Erl, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 24, 2016
<sup>68</sup>Ga-PSMA-11 PET as a Gatekeeper for the Treatment of Metastatic Prostate Cancer with <sup>223</sup>Ra: Proof of ConceptHojjat Ahmadzadehfar, Kambiz Azgomi, Stefan Hauser, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 27, 2018
Outcome and safety of rechallenge [<sup>177</sup>Lu]Lu-PSMA-617 in patients with metastatic prostate cancerAnna Yordanova, Paula Linden, Stefan Hauser, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 4, 2007
Postacquisition detection of tumor motion in the lung and upper abdomen using list-mode PET data: a feasibility studyRalph A Bundschuh, Axel Martínez-Moeller, Markus Essler, et al.
Oncotarget|May 2, 2019
Diagnosis of peri-prosthetic loosening of total hip and knee arthroplasty using <sup>18</sup>F-Fluoride PET/CTSebastian Koob, Florian C Gaertner, Tom Rainer Jansen, et al.
International Journal of Molecular Sciences|August 12, 2023
Cytokine-Induced Killer Cells in Combination with Heat Shock Protein 90 Inhibitors Functioning via the Fas/FasL Axis Provides Rationale for a Potential Clinical Benefit in Burkitt's lymphomaFangfang Ge, Yulu Wang, Amit Sharma, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 23, 2018
<sup>68</sup>Ga-PSMA-PET/CT imaging of localized primary prostate cancer patients for intensity modulated radiation therapy treatment planning with integrated boostLena Thomas, Steffi Kantz, Arthur Hung, et al.
Nuklearmedizin. Nuclear Medicine|April 29, 2020
[177Lu]Lu-DOTA-zoledronate therapy - first application in a patient with primary osseous metastatic bronchial carcinomaBarbara Kreppel, Florian Christoph Gaertner, Hojjat Ahmadzadehfar, et al.
Annals of Nuclear Medicine|March 17, 2019
Preliminary results of biodistribution and dosimetric analysis of [<sup>68</sup>Ga]Ga-DOTA<sup>ZOL</sup>: a new zoledronate-based bisphosphonate for PET/CT diagnosis of bone diseasesAmbreen Khawar, Elisabeth Eppard, Frank Roesch, et al.
Frontiers in Nuclear Medicine|October 2, 2024
Multicentric <sup>68</sup>Ga-PSMA PET radiomics for treatment response assessment of <sup>177</sup>Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancerRobin Gutsche, Gizem Gülmüs, Felix M Mottaghy, et al.
Pageof 21